Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

14.65 -0.44 (-2.92%)
Streaming Delayed Price Updated: 2:42 PM EDT, Mar 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about HUTCHMED (China) Limited - American Depositary Shares

< Previous 1 2 3 4 Next >
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Reports 2023 Interim Results and Provides Business Updates
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces Changes to Board of Directors and Technical Committee
Ms Ling Yang to replace Mr Lefei Sun as Non-executive Director; Professor Solange Peters appointed as Special Advisor to the Technical Committee 
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED to Announce 2023 Half-Year Financial Results
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
From HUTCHMED (China) Limited
Via GlobeNewswire
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings
From HUTCHMED (China) Limited
Via GlobeNewswire
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting
From HUTCHMED (China) Limited
Via GlobeNewswire
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
HUTCHMED Announces Board of Directors and Board Committee Membership
From HUTCHMED (China) Limited
Via GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
From Virtual Investor Conferences
Via GlobeNewswire
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees
From HUTCHMED (China) Limited
Via GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
From Virtual Investor Conferences
Via GlobeNewswire
HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023
From HUTCHMED (China) Limited
Via GlobeNewswire
Intended Retirement of Independent Non-executive Director
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Confirms No Assets Held at Silicon Valley Bank
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Reports 2022 Full Year Results and Provides Business Updates
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED to Announce 2022 Final Results
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China
From HUTCHMED (China) Limited
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.